Your donation will make a difference:
Cystic Fibrosis Trust
Forum

Trials Tracker

Welcome to the Trials Tracker, bringing together all the cystic fibrosis (CF) trials currently recruiting in the UK so that you can find clinical trials you can take part in both in your region and further afield. The Trials Tracker is a new resource that we’ll be developing over time based on your feedback. If you’ve used the Trials Tracker and want to share your opinion, please complete our online poll or get in touch at clinicaltrials@cysticfibrosis.org.uk.

Please Log in

Log in

Not a registered user? Register with us

This trial has been added to your watchlist.

Do you want to receive email notifications when the trial status changes?

No Yes

Unfollowing a trial will remove it from the watchlist and stop status change email notifications

Are you sure you want to unfollow this trial?

Yes, remove from watchlist

Clinical trials

6-10 of 44 results for all trials

Sort by:

Filter by

Trial status

Inclusion age

FEV1

Trial type

Location

Mutation

Therapeutic category

A Study Evaluating the Long Term Safety and Efficacy of VX-659 Combination Therapy (VX17-659-105)

This study will evaluate the long-term safety and tolerability of VX-659 in triple combination with Tezacaftor and Ivacaftor in subjects with cystic fibrosis (CF), including but not limited to those who are heterozygous for the F508del mutation

Phase III
  • Trial Reference Number

    108792

  • Trial status

    Open to recruitment

  • Therapeutic category

    Restore CFTR Function

Trial to Evaluate Efficacy and Safety of Lenabasum in Cystic Fibrosis

This is a Phase 2 multicenter, double-blind, randomized, placebo-controlled study assessing the efficacy and safety of lenabasum for the treatment of cystic fibrosis in patients 12 years of age or older. Approximately 415 subjects will be enrolled in this study

Read more Phase II
  • Trial Reference Number

    106210

  • Trial status

    Open to recruitment

  • Therapeutic category

    Anti-Inflammatory

Remote monitoring & gaming technology for improving outcomes in children with cystic fibrosis

Remote monitoring and gaming technology for improving physiotherapy prescription, adherence and prediction of clinical outcomes in children with cystic fibrosis. Airway clearance, physical activity and exercise can mitigate the progression of CF lung disease, but routine physiotherapy treatments are burdensome and adherence is low. Traditional research has failed to produce credible evidence to guide practice, partly because ‘blinding’ isn’t possible and patient preference can confound results. Following our involvement with the ‘Big Life Fix’ television series https://youtu.be/d6A8R146JWU (BBC2,2016) we have worked with engineers and designers to develop electronically chipped airway clearance devices and wearable activity trackers to facilitate automatic data transmission to clinicians and researchers caring for children with CF. Industry partners (Microsoft) and UCL computer science experts are helping us develop computer games driven by breathing through an airway clearance device (to enhance treatment enjoyment and adherence). The project will use this technology for passive remote capture and transmission of daily longitudinal data during airway clearance, physical activity and exercise to assess impact on clinical outcomes. Innovative big data analysis methods will be used to find out whether: Children with CF should do regular ACTs or exercise, and what the minimum effective dose is physical activity levels have an impact on clinical outcomes airway clearance or exercise is more effective in different children (and how to choose) some airway clearance techniques are better than others airway clearance gaming helps children do treatments more regularly, and whether better adherence improves health alternative to traditional research methods and help identify sensitive composite outcome measures for children with mild signs and symptoms.

Read more Study
  • Trial Reference Number

    97027

  • Length of participation

    14 months

  • Trial status

    Open to recruitment

  • Therapeutic category

    Behavioral

ALPINE 2: AZLI for children with CF and PA lung infection

The primary objective of this study is to evaluate the safety and efficacy of a 14-day course versus a 28-day course of aztreonam for inhalation solution (AZLI) in participants with new onset Pseudomonas aeruginosa respiratory tract infection.

Phase III
  • Trial Reference Number

    88959

  • Length of participation

    28 days

  • Trial status

    Open to recruitment

  • Therapeutic category

    Anti-Infective

Glycaemic Index Dietary Education for glucose abnormalities in Cystic Fibrosis

Few people with Cystic Fibrosis have normal blood glucose control and these glucose abnormalities eventually progress to cystic fibrosis-related diabetes (CFRD), the most common complication of Cystic Fibrosis. People with Cystic Fibrosis are encouraged to consume a high calorie diet to maintain weight. This typically means eating food and drinks that are often high in fat and/or sugar. For people with Cystic Fibrosis who also need to control their blood glucose levels, high sugar intake can make this difficult. There is limited evidence to guide dietary therapy for blood glucose abnormalities in Cystic Fibrosis. Manipulating the glycaemic index (GI) and glycaemic load (GL) of what is consumed may be a possible area for intervention to improve blood glucose control without compromising energy intake. This study will explore the feasibility of delivering glycaemic index/glycaemic load dietary education (GLIDE) in a sample of 20 young people with CF and abnormal blood glucose control. GLIDE intervention will be implemented by participants for 12 weeks. Dietary intake and glycaemic control will be measured at baseline and at 12 week follow-up using an on-line dietary recording tool and continuous glucose monitoring, respectively. The primary objective of this study is to investigate the feasibility of GLIDE intervention in young people with CF and abnormal blood glucose control. Secondary objectives include measuring glycaemic control, energy and nutrient intake, body weight and lung function before GLIDE intervention and at 12-week follow-up.

Read more Not Applicable
  • Trial Reference Number

    107989

  • Length of participation

    4 months

  • Trial status

    Open to recruitment

  • Therapeutic category

    Nutritional-GI

6-10 of 44 results for all trials